The primary objective of this study is:
• To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Who can participate
Inclusion Criteria:
1. Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures.
2. Subject must have completed all 24 weeks of participation in the study C-935788-057.
Exclusion Criteria:
1\. Any subject who discontinued participation in Study C-935788-057 prior to Week 24.
Locations
16
Australia (1)
Princess Alexandra Hospital - Cancer Trials Unit
Brisbane , Queensland
Belarus (1)
Vitebsk Regional Clinical Hospital
Vitebsk
Bulgaria (1)
University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD, Plovdiv, Clinic of Medical oncology
Pleven
Czech Republic (1)
Fakultni nemocnice Brno Interni hematologicka a onkologicka klinika
Brno
France (1)
CHU de Bordeaux - GH Sud- Hôpital Haut Lévêque Service Médecine Interne et Maladies Infectieuses
Pessac
Georgia (1)
LTD Multiprofile Clinic Consilium Medulla
Tbilisi
Germany (1)
Universitätsklinikum Essen
Essen
Italy (1)
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, UO Ematologia
Milan
Netherlands (1)
Academisch Medisch Centrum
Amsterdam
Norway (1)
Haukeland University Hospital
Bergen
Russia (1)
National Research Center for Hematology
Moscow
Serbia (1)
Clinical Centre of Vojvodina, Clinic for Hematology
Novi Sad
Spain (1)
Hospital Vall d'Hebron
Barcelona
Ukraine (1)
City Clinical Hospital № 4, Hematology Center
Dnipro
United Kingdom (1)
Roald Dahl Haemostasis and Thrombosis Centre, Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust
Liverpool
United States (1)
University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory
БГ